Omalizumab (Drug Plan Submission)

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Asthma, severe persistent

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Call for patient/clinician input open:

October 6, 2015

Brand Name:

Xolair

Project Line:

Reimbursement Review

Project Number:

SR0457-000

Call for patient/clinician input closed:

November 25, 2015

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Drug Plan Initiated

Indications:

Asthma, severe persistent

Recommendation Type:

Reimburse with clinical criteria and/or conditions

Final Recommendation:

May 18, 2016

Last Updated : October 6, 2015